Headlines about Deciphera Pharmaceuticals (NASDAQ:DCPH) have trended somewhat negative this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Deciphera Pharmaceuticals earned a news impact score of 0.00 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 47.9752212157359 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the headlines that may have impacted Accern’s rankings:
- Preclinical Data Demonstrate That Deciphera Pharmaceuticals’ DCC-2618 Exhibits Broader Inhibition Profile Against Primary and Secondary Drug-Resistant Mutations in … (businesswire.com)
- Preclinical Data Demonstrate That Deciphera Pharmaceuticals’ DCC-2618 Exhibits Broader Inhibition Profile Against Primary and Secondary Drug-Resistant Mutations in Gastrointestinal Stromal Tumors (GIST) Compared to Approved and Investigational Agents (finance.yahoo.com)
- -$0.64 Earnings Per Share Expected for Deciphera Pharmaceuticals (DCPH) This Quarter (americanbankingnews.com)
- Deciphera Pharmaceuticals (DCPH) Upgraded at BidaskClub (americanbankingnews.com)
A number of analysts recently issued reports on DCPH shares. BidaskClub lowered Deciphera Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, March 15th. B. Riley started coverage on Deciphera Pharmaceuticals in a research note on Friday, February 16th. They set a “buy” rating and a $43.00 price objective on the stock. Finally, Zacks Investment Research upgraded Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 price objective on the stock in a research note on Monday, December 25th. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $41.14.
NASDAQ:DCPH opened at $23.56 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 14.35 and a quick ratio of 14.35. Deciphera Pharmaceuticals has a 52-week low of $15.15 and a 52-week high of $29.98.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its quarterly earnings data on Wednesday, March 28th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.19). analysts forecast that Deciphera Pharmaceuticals will post -2.36 earnings per share for the current year.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company develops DCC-2618, a pan-KIT and pan-PDGFRa inhibitor for the treatment of gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors.
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.